178 related articles for article (PubMed ID: 37531029)
21. Inflammatory Factors of Macular Atrophy in Eyes With Neovascular Age-Related Macular Degeneration Treated With Aflibercept.
Sato T; Enoki T; Karasawa Y; Someya H; Taguchi M; Harimoto K; Takayama K; Kanda T; Ito M; Takeuchi M
Front Immunol; 2021; 12():738521. PubMed ID: 34721402
[TBL] [Abstract][Full Text] [Related]
22. Verteporfin photodynamic therapy for neovascular age-related macular degeneration: cohort study for the UK.
Reeves BC; Harding SP; Langham J; Grieve R; Tomlin K; Walker J; Guerriero C; Carpenter J; Patton WP; Muldrew KA; Peto T; Chakravarthy U
Health Technol Assess; 2012; 16(6):i-xii, 1-200. PubMed ID: 22348600
[TBL] [Abstract][Full Text] [Related]
23. Visual Acuity Outcomes and Anti-Vascular Endothelial Growth Factor Therapy Intensity in Neovascular Age-Related Macular Degeneration Patients: A Real-World Analysis of 49 485 Eyes.
Ciulla TA; Hussain RM; Pollack JS; Williams DF
Ophthalmol Retina; 2020 Jan; 4(1):19-30. PubMed ID: 31324588
[TBL] [Abstract][Full Text] [Related]
24. Creation of a neovascular age-related macular degeneration national database using a web-based platform: Fight Retinal Blindness Spain. Report 1: Visual outcomes.
Zarranz-Ventura J; Parrado-Carrillo A; Nguyen V; Sararols L; Garay-Aramburu G; Puzo M; Arruabarrena C; Figueras-Roca M; Gillies MC; Casaroli-Marano RP;
Clin Exp Ophthalmol; 2022 Apr; 50(3):312-324. PubMed ID: 35106882
[TBL] [Abstract][Full Text] [Related]
25. Long-Term Visual Outcomes for a Treat-and-Extend Antivascular Endothelial Growth Factor Regimen in Eyes with Neovascular Age-Related Macular Degeneration: Up to Seven-Year Follow-Up.
Javidi S; Dirani A; Antaki F; Saab M; Rahali S; Cordahi G
J Ophthalmol; 2020; 2020():3207614. PubMed ID: 32802487
[TBL] [Abstract][Full Text] [Related]
26. Treatment patterns for retinal diseases in patients newly-treated with anti-VEGF agents: A retrospective analysis of claims data from the Japan Medical Data Center database.
Kawasaki R; Bauer M; Bezlyak V; Ogura Y
Jpn J Ophthalmol; 2021 Mar; 65(2):215-226. PubMed ID: 33420855
[TBL] [Abstract][Full Text] [Related]
27. Management and Outcomes for Neovascular Age-Related Macular Degeneration: Analysis of United States Electronic Health Records.
Kiss S; Campbell J; Almony A; Shih V; Serbin M; LaPrise A; Wykoff CC
Ophthalmology; 2020 Sep; 127(9):1179-1188. PubMed ID: 32345477
[TBL] [Abstract][Full Text] [Related]
28. Macular Atrophy Incidence and Progression in Eyes with Neovascular Age-Related Macular Degeneration Treated with Vascular Endothelial Growth Factor Inhibitors Using a Treat-and-Extend or a Pro Re Nata Regimen: Four-Year Results of the MANEX Study.
Spooner KL; Fraser-Bell S; Cozzi M; Staurenghi G; Invernizzi A; Monteduro D; Munk MR; Hong T; Chang AA
Ophthalmology; 2020 Dec; 127(12):1663-1673. PubMed ID: 32544561
[TBL] [Abstract][Full Text] [Related]
29. Burden of diabetic macular oedema in patients receiving antivascular endothelial growth factor therapy in South Korea: a healthcare resource use and cost analysis.
Jeon HL; Lee H; Yoon D; Lee Y; Kim JH; Jee D; Shin JY
BMJ Open; 2020 Dec; 10(12):e042484. PubMed ID: 33376178
[TBL] [Abstract][Full Text] [Related]
30. A Retrospective Study of Ranibizumab Treatment Regimens for Neovascular Age-Related Macular Degeneration (nAMD) in Australia and the United Kingdom.
Johnston RL; Carius HJ; Skelly A; Ferreira A; Milnes F; Mitchell P
Adv Ther; 2017 Mar; 34(3):703-712. PubMed ID: 28144918
[TBL] [Abstract][Full Text] [Related]
31. Intravitreal anti-VEGF use in France: a cross-sectional and longitudinal Nationwide observational study.
Billioti de Gage S; Bertrand M; Grimaldi S; Zureik M
Acta Ophthalmol; 2022 Mar; 100(2):e502-e511. PubMed ID: 34126649
[TBL] [Abstract][Full Text] [Related]
32. Effects of suspension of anti-vascular endothelial growth factor treatment for neovascular age-related macular degeneration in clinical setting.
Matsubara H; Matsui Y; Miyata R; Ichio A; Chujo S; Enomoto H; Sugimoto M; Kondo M
Graefes Arch Clin Exp Ophthalmol; 2022 Jun; 260(6):1867-1876. PubMed ID: 35094126
[TBL] [Abstract][Full Text] [Related]
33. Impact of intravitreal ranibizumab, aflibercept and bevacizumab on retinal ganglion cell and nerve fibre layer thickness in Neovascular age-related macular degeneration.
Abu Dail Y; Seitz B; Sideroudi H; Abdin AD
Acta Ophthalmol; 2023 May; 101(3):330-341. PubMed ID: 36345883
[TBL] [Abstract][Full Text] [Related]
34. [Electrophysiological study of the visual pathway in anti-VEGF therapy of neovascular age-related macular degeneration combined with glaucoma].
Smirnova TV; Rud'ko AS; Andreeva IV; Karpilova MA
Vestn Oftalmol; 2019; 135(5):38-45. PubMed ID: 31714511
[TBL] [Abstract][Full Text] [Related]
35. Clinical and economic burden of neovascular age-related macular degeneration by disease status: a US claims-based analysis.
Almony A; Keyloun KR; Shah-Manek B; Multani JK; McGuiness CB; Chen CC; Campbell JH
J Manag Care Spec Pharm; 2021 Sep; 27(9):1260-1272. PubMed ID: 34464210
[No Abstract] [Full Text] [Related]
36. Visual acuity outcomes of anti-VEGF treatment for neovascular age-related macular degeneration in clinical trials.
Yamashiro K; Oishi A; Hata M; Takahashi A; Tsujikawa A
Jpn J Ophthalmol; 2021 Nov; 65(6):741-760. PubMed ID: 34491474
[TBL] [Abstract][Full Text] [Related]
37. Risk of Systemic Adverse Events after Intravitreal Bevacizumab, Ranibizumab, and Aflibercept in Routine Clinical Practice.
Maloney MH; Payne SR; Herrin J; Sangaralingham LR; Shah ND; Barkmeier AJ
Ophthalmology; 2021 Mar; 128(3):417-424. PubMed ID: 32781110
[TBL] [Abstract][Full Text] [Related]
38. Cost of Ranibizumab Port Delivery System vs Intravitreal Injections for Patients With Neovascular Age-Related Macular Degeneration.
Sood S; Mandell J; Watane A; Friedman S; Parikh R
JAMA Ophthalmol; 2022 Jul; 140(7):716-723. PubMed ID: 35708679
[TBL] [Abstract][Full Text] [Related]
39. Intraocular and systemic inflammation-related cytokines during one year of ranibizumab treatment for neovascular age-related macular degeneration.
Fauser S; Viebahn U; Muether PS
Acta Ophthalmol; 2015 Dec; 93(8):734-8. PubMed ID: 26016605
[TBL] [Abstract][Full Text] [Related]
40. Complete RPE and outer retinal atrophy in patients receiving anti-VEGF treatment for neovascular age-related macular degeneration.
Eng VA; Rayess N; Nguyen HV; Leng T
PLoS One; 2020; 15(5):e0232353. PubMed ID: 32369500
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
